World ReportEU implicated in controversial counterfeiting bill
References (0)
Cited by (10)
An empirical review of antimalarial quality field surveys: the importance of characterising outcomes
2018, Journal of Pharmaceutical and Biomedical AnalysisCitation Excerpt :This difference is partially attributed to the conflicting interests of pharmaceutical companies and public health organisations [7]. The lack of clear distinctions between categories of PQMs has led to confusion, with companies protecting their patents from generic versions using the definition meant to protect against criminally counterfeited reproductions and distracting from countering other types of PQM [8,9]. This limitation led to some countries’ regulatory authorities interpreting model definitions to view counterfeit products as an intellectual property (IntPro) issue, resulting in an adverse effect on the international trade of quality generic medicine [10,11].
A counterfeit drug treaty: Great idea, wrong implementation
2010, The LancetIntellectual property and the life sciences in Kenya: Enforcement and access to medicines
2017, Research Handbook on Intellectual Property and the Life Sciences: Research Handbooks in Intellectual Property SeriesFraming the national interest: Debating intellectual property and access to essential medicines in Kenya
2014, Journal of World Intellectual Property
Copyright © 2010 Published by Elsevier Ltd. All rights reserved.